Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana : a cross-sectional study by Mwita, Julius Chacha et al.
1Mwita JC, et al. BMJ Open 2019;9:e026807. doi:10.1136/bmjopen-2018-026807
Open access 
Glycaemic, blood pressure and low-
density lipoprotein-cholesterol control 
among patients with diabetes mellitus 
in a specialised clinic in Botswana: a 
cross-sectional study
Julius Chacha Mwita,   1,2 Joel M Francis,3,4 Bernard Omech,1,2 Elizabeth Botsile,1,2 
Aderonke Oyewo,2 Matshidiso Mokgwathi,1,2 Onkabetse Julia Molefe-Baikai,1,2 
Brian Godman,5,6,7 Jose-Gaby Tshikuka8,9
To cite: Mwita JC, Francis JM, 
Omech B, et al.  Glycaemic, 
blood pressure and low-density 
lipoprotein-cholesterol control 
among patients with diabetes 
mellitus in a specialised 
clinic in Botswana: a cross-
sectional study. BMJ Open 
2019;9:e026807. doi:10.1136/
bmjopen-2018-026807
 ► Prepublication history for 
this paper is available online. 
To view these files please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
026807).
Received 20 September 2018
Revised 14 May 2019
Accepted 03 July 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Julius Chacha Mwita;  
 mwitajc@ ub. ac. bw
Research
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Objective Control of glycaemic, hypertension and low-
density lipoprotein-cholesterol (LDL-C) among patients 
with type 2 diabetes mellitus (T2DM) is vital for the 
prevention of cardiovascular diseases. The current study 
was an audit of glycaemic, hypertension and LDL-C control 
among ambulant patients with T2DM in Botswana. Also, 
the study aimed at assessing factors associated with 
attaining optimal glycaemic, hypertension and LDL-C 
therapeutic goals.
Design A cross-sectional study.
setting A specialised public diabetes clinic in Gaborone, 
Botswana.
Participants Patients with T2DM who had attended the 
clinic for ≥3 months between August 2017 and February 
2018.
Primary outcome measure The proportion of patients 
with optimal glycaemic (HbA1c<7%), hypertension (blood 
pressure <140/90 mm Hg) and LDL-C (<1.8 mmol/L) 
control.
results The proportions of patients meeting optimal 
targets were 32.3% for glycaemic, 54.2% for hypertension 
and 20.4% for LDL-C. Age≥ 50 years was positively 
associated with optimal glycaemic control (adjusted OR 
[AOR] 5.79; 95% CI 1.08 to 31.14). On the other hand, an 
increase in diabetes duration was inversely associated 
with optimal glycemic control (AOR 0.91; 95% CI 0.85 to 
0.98). Being on an ACE inhibitor was inversely associated 
with optimal hypertension control (AOR 0.35; 95% CI 
0.14 to 0.85). Being female was inversely associated with 
optimal LDL-C control (AOR 0.24; 95% CI (0.09 - 0.59).
Conclusion Patients with T2DM in Gaborone, Botswana, 
presented with suboptimal control of recommended 
glycaemic, hypertension and LDL-C targets. These findings 
call for urgent individual and health systems interventions 
to address key determinants of the recommended 
therapeutic targets among patients with diabetes in this 
setting.
IntrODuCtIOn
Diabetes mellitus and related cardiovascular 
complications are growing public health 
concerns worldwide.1 2 There are approx-
imately 16 million people with diabetes 
in Africa, and this number is projected to 
increase to 41 million by 2045 due to rapid 
urbanisation, lifestyles changes and nutrition 
transition in the continent.1 This increase 
in prevalence and incidence of diabetes is 
attributable to type 2 diabetes, which is asso-
ciated with multiple comorbidities such as 
obesity and hypertension requiring chronic 
care and catastrophic health expenditure.1 
Diabetes and associated comorbidities are 
known to increase patients’ risk of devel-
oping cardiovascular diseases (CVDs), which 
are responsible for approximately 70% of 
diabetes-related deaths.3 4 The risk to the 
development of CVD is higher in people 
with suboptimal glycaemic, hypertension 
and low-density lipoprotein-cholesterol 
(LDL-C) control.3 5 A reduction of HbA1c to 
control targets along with optimal hyperten-
sion control and the use of statins to lower 
LDL-C levels have been shown to improve 
strengths and limitations of this study
 ► The first study to objectively assess the three criti-
cal therapeutic targets in patients with diabetes in 
Botswana.
 ► The study was undertaken in one specialised public 
diabetes clinic, and the findings may not be gener-
alised to other facilities in the country.
 ► The cross-sectional design limited the assessment 
of the temporal relationship between factors asso-
ciated with poor control of glycaemia, low-density 
lipoprotein-cholesterol and hypertension.
 ► Systematic random sampling and incomplete data 
in some participants may not have yielded a repre-
sentative sample of our clinic enrolees.
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long-term outcomes including reducing mortality among 
patients with diabetes.6–9 Achieving these targets remains 
a challenge in most settings, especially those with limited 
access to standard diabetes care.10–16 Only a minority of 
patients with diabetes in Africa achieves optimal thera-
peutic targets, leaving the majority of patients at high risk 
of diabetes-related complications.13 15 Suboptimal treat-
ment to recommended targets is a public health concern 
because the current total health expenditure in most 
sub-Saharan African countries remains far below the 15% 
recommended in the Abuja declaration.17 The rising cost 
of managing diabetes complications will further make 
health system goals unattainable.1 Thus, this study was 
an audit of glycaemic, hypertension and LDL-C control 
among ambulant patients with type 2 diabetes mellitus in 
Botswana. The study also assessed factors associated with 
the attainment of glycaemic, blood pressure and LDL-C 
therapeutic targets in these patients.
MethODs
study design and participants
We conducted a cross-sectional study of outpatients with 
established type 2 diabetes attending a specialised public 
diabetes clinic in Gaborone, Botswana between August 
2017 and February 2018. The clinic has been opera-
tional since 2011 as a referral centre for health facilities 
in Gaborone and nearby towns. Eligible patients were 
those aged ≥18 years and had received care from the 
clinic for at least 3 months. We needed a sample size of 
500 to produce a two-sided 95% CI with a width equal to 
3.86% based on the assumptions of approximately 26.2% 
glycaemic control among patients with type 2 diabetes 
in Botswana.16 Systematic random sampling was used 
to select patients from a list of patients who attended 
the clinic every day. In a recruitment day, we randomly 
picked the first patient from the list of the first eight 
clinic attendees. Subsequently, we enrolled every eighth 
individual until either the daily target of 10 patients was 
reached or the clinic came to an end. As there was a daily 
variation of the number of clinic attendees, the number 
of our daily enrolments varied as well.
Data collection and procedures
Patient information was collected using an interview-
er-administered questionnaire and through reviews of 
medical charts and electronic records. The information 
included demographic data (age, gender, occupation, 
marital status and education), diabetes duration, history 
of hypertension, and medications for diabetes, hyperten-
sion and lipid disorders. We performed anthropometry 
(weight, height, waist and hip circumferences) and blood 
pressure measurements at enrolment. We conducted 
three blood pressure measurements after 10 min of rest, 
and the mean of the three measurements was recorded.18 
Moreover, we documented blood pressure readings from 
each patient’s previous visit. Patients’ serum creatinine, 
LDL-C and HbA1c, and urine dipstick for proteinuria 
results over the past 6 months were abstracted from the 
electronic medical records.
Definitions of the key outcomes and exposure variables
We calculated the diabetes duration as the date of 
enrolment into the study minus the date of a diabetes 
diagnosis. A patient was considered hypertensive by 
self-reported hypertension and the use of blood pres-
sure–lowering medications or had sustained blood pres-
sure ≥140/90 mm Hg during the previous visit and at 
enrolment.19–21 Optimal glycaemic control was defined 
as HbA1c <7%.19 21 For patients who were on lipid-low-
ering medications, optimal LDL-C control was LDL-C 
level <1.8 mmol/L.19 We calculated patients’ estimated 
glomerular filtration rate (eGFR) by the Modification of 
Diet in Renal Disease formula, and an eGFR <60.0 mL/
min/1.73 m2 defined chronic kidney disease.2 22 23 Body 
mass index (BMI) was calculated as weight in kilograms 
divided by the square of height in metres. We consid-
ered underweight as BMI <18.5 kg/m2, normal weight as 
BMI of 18.5–24.9 kg/m2, overweight as BMI of 25.0–29.9 
kg/m2 and obesity as BMI ≥30 kg/m2.24 Waist:hip ratio 
(WHR) was calculated as waist circumference in centime-
tres divided by hip circumference in centimetres and clas-
sified as high when WHR was ≥0.85 and ≥0.90 for women 
and men, respectively.24
Patient and public involvement
We did not directly involve patients in the design, recruit-
ment to and conduct of the study. However, the devel-
opment of the research question and outcome measures 
were informed by patients’ priorities, experience and 
preferences. These were realised during the regular 
diabetes support group meetings where the authors of 
this study interact with patients and their families. Investi-
gators working at the clinic will discuss the study findings 
with colleagues and provide them with critical results for 
sharing with patients (study participants). In close collab-
oration with the patient support group, the investigation 
team will summarise the results in plain language for a 
large poster and place it in a waiting room.
statistical analysis
We performed analyses using Stata V.14 (Stata Corp, 
College Station, Texas, USA). We used percentages to 
summarise categorical variables. Means and SD or medians 
and IQR were used to summarise continuous variables. 
Pearson’s χ2 or Fisher’s exact test was used to assess statis-
tical differences by gender for the categorical variables, 
while Student’s t-test or the Mann-Whitney U test was 
used for the continuous ones. Bivariate logistic regression 
was used to explore factors associated with each primary 
outcome—glycaemic, hypertension and LDL-C control. 
We further performed three multivariate logistic regres-
sion models for each of the three outcomes. The indepen-
dent variables selected for multivariate models were those 
displaying a p value <0.2 at the univariate analysis level in 
addition to those considered clinically meaningful (age 
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Table 1 Clinical and sociodemographic characteristics of patients with type 2 diabetes at a specialised diabetes clinic in 
Gaborone (N=500)
Characteristics All (N=500) Men (n=170) Women (n=330) P value
Mean age (SD), years 58.9 (12.2) 55.4 (12.6) 60.8 (11.6) <0.001
Age <50 years n (%) 109 (21.80) 57 (33.5) 52 (15.8) <0.001
Age ≥50 years n (%) 391 (78.20) 113 (66.5) 278 (84.2)
Diabetes duration, median (IQR), years 6 (2–13) 6.5 (2–14) 6 (2.5–13) 0.927
HbA1c mean (SD), % 8.4 (2.4) 8.6 (2.7) 8.4 (2.4) 0.199
Diabetes treatment
  Diet alone n (%) 11 (2.2) 3 (1.8) 8 (2.4) 0.001
  Insulin alone n (%) 68 (13.6) 38 (22.3) 30 (9.1)
  OHA alone n (%) 271 (54.2) 82 (48.2) 189 (57.3)
  Insulin and OHA 150 (30.0) 47 (27.7) 103 (31.2)
BMI, mean (SD), kg/m2 30.5 (6.0) 28.7 (5.2) 31.4 (6.2 <0.001
  Normal weight n (%) 93 (18.7) 46 (27.1) 49 (14.9) <0.001
  Overweight n (%) 155 (31.1) 61 (36.3) 94 (28.5)
  Obese n (%) 250 (50.2) 63 (37.1) 187 (56.7)
Marital status
  Living alone n (%) 266 (53.20) 55 (32.4) 211 (63.9) <0.001
  Living with a partner n (%) 234 (46.8) 115 (67.6) 119 (36.01)
Education status
  No formal education, n (%) 77 (15.4) 26 (15.3) 51 (15.5) <0.001
  Primary school, n (%) 229 (45.8) 56 (32.9) 173 (52.4)
  Secondary school, n (%) 131 (26.2) 55 (32.4) 76 (23.0)
  College/university, n (%) 63 (12.6) 33 (19.4) 30 (9.1)
WC, mean (SD), cm 103.3 (12.5) 101.7 (11.9) 104.0 (12.7) 0.049
WHR 0.94 (0.10) 0.97 (0.09) 0.93 (0.10) <0.001
  Low WHR n (%) 75 (44.1) 16 (4.9) <0.001
  High WHR n (%) 95 (55.9) 314 (95.2)
CKD n (%) 54 (10.8) 24 (14.1) 30 (9.1) 0.086
eGFR, median, IQR
(mL/min/1.73 m²)
112.5 (84.3–138.1) 113.1 (80.8–139.5) 112.3 (84.4–137.9) 0.737
Cholesterol, mean (SD), mmol/L 4.4 (1.1) 4.3 (1.2) 4.5 (1.1) 0.030
LDL-C mean (SD), mmol/L 2.8 (1.0) 2.6 (1.0) 2.9 (1.0) 0.006
Proteinuria n (%) 51 (10.20) 27 (15.9) 24 (7.27) 0.003
Hypertension n (%) 404 (80.80) 120 (70.59) 284 (86.06) <0.001
Dyslipidaemia n (%) 358 (71.60) 114 (67.06) 244 (73.94) 0.106
BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein-cholesterol; 
OHA, oral hypoglycaemic agent; WC, waist circumference; WHR, waist:hip ratio.
and gender). We described results as crude OR, adjusted 
OR (AOR) and their corresponding 95% CIs. We used 
the Hosmer-Lemeshow goodness-of-fit test to assess how 
well the data fit the model.25 A two-tailed p value <0.05 
was considered statistically significant.
results
The response rate was 97%, as only 17 (3.4%) of the 
approached participants declined participation because 
of time constraints. We included 500 patients with type 2 
diabetes in the study, of which 330 (66%) were women. 
The mean (SD) age was 58.9 (12.2) years, and 78.2% 
were aged >50 years. The median (IQR) diabetes dura-
tion was 6 (2–13) years. There was a high percentage 
of patients with hypertension (80.8%), overweight 
(31.1%) and obesity (50.2%). Table 1 summarises the 
patients’ characteristics by gender. Female patients 
tended to be older (60.8 vs 55.4 years, p<0.001), obese 
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Table 2 Factors associated with optimal glycaemic control among patients with type 2 diabetes at a specialised diabetes 
clinic in Gaborone (N=500)
Characteristic Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Age group
  >50 years 1
  ≤50 years 2.16 (1.29 to 3.61) 0.003 5.79 (1.08 to 31.14) 0.041
Diabetes duration, years 0.97 (0.95 to 0.99) 0.040 0.91 (0.85 to 0.98) 0.011
Use of insulin alone
  No 1
  Yes 0.80 (0.45 to 1.43) 0.590
Use of OHA alone
  No 1
  Yes 2.785 (1.862 to 4.167) <0.001 0.90 (0.46 to 1.74) 0.745
Use of insulin plus OHA
  No 1
  Yes 0.185 (0.124 to 0.356) <0.001 0.34 (0.07 to 1.70) 0.188
BMI 0.99 (0.96 to 1.02) 0.427 – –
  Normal weight 1 – – –
  Overweight 1.10 (0.64 to 1.90) 0.721 – –
  Obese 0.83 (0.50 to 1.39) 0.476 – –
Gender – –
  Male 1 – – –
  Female 0.92 (0.62 to 1.36) 0.663 0.42 (0.14 to 1.25) 0.120
Education status
  None 1 1 – –
  Primary school 1.58 (0.88 to 2.81) 0.124 – –
  Secondary school 1.14 (0.60 to 2.16) 0.687 – –
  College/university 1.00 (0.47 to 2.13) 0.996 – –
Marital status
  Living alone 1 – – –
  Living with a partner 0.93 (0.64 to 1.36) 0.703 – –
WHR 0.92 (0.13 to 6.58) 0.937 –
  Low WHR 1 – – –
  High WHR 0.92 (0.57 to 1.50) 0.745 – –
Weight, kg 0.99 (0.98 to 1.01) 0.298 –
eGFR (mL/min/1.73 m²) 1.00 (0.99 to 1.00) 0.074 1.00 (0.99 to 1.01) 0.766
CKD
  No 1
  Yes 1.053 (0.578 to 1.920) 0.866 – –
Proteinuria
  No 1 –
  Yes 1.16 (0.63 to 2.14) 0.624 – –
Optimal hypertension control
  No 1 –
  Yes 2.53 (1.63 to 3.93) <0.001 1.61 (0.63 to 4.13) 0.322
Optimal LDL-C control
  No 1
  Yes 2.10 (0.90 to 4.88) 0.086 2.20 (0.64 to 7.57) 0.209
BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein-cholesterol; OHA, 
oral hypoglycaemic agent; WHR, waist:hip ratio.
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Table 3 Factors associated with optimal hypertension control among patients with type 2 diabetes at a specialised diabetes 
clinic in Gaborone (N=500)
Characteristic Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Age group
  <50 years 1 – – –
  ≥50 years 0.89 (0.48 to 1.62) 0.691 – –
Diabetes duration, years 0.97 (0.94 to 0.99) 0.023 0.98 (0.92 to 1.03) 0.352
Use of insulin alone
  No 1 – – –
  Yes 0.45 (0.24 to 0.82) 0.009 1.15 (0.30 to 4.44) 0.837
Use of OHA alone
  No – – –
  Yes 1.94 (1.30 to 2.91) 0.001 1.37 (0.51 to 3.66) 0.531
Use of insulin plus OHA
  No 1 – – –
  Yes 0.59 (0.40 to 0.95) 0.028* – –
BMI, kg/m2 0.98 (0.94 to 1.01) 0.149 0.93 (0.86 to 1.01)
  Normal weight 1 – –
  Overweight 0.79 (0.42 to 1.47) 0.449 – –
  Obese 0.77 (0.44 to 1.38) 0.384 – –
Gender
  Male 1 – – –
  Female 1.43 (0.92 to 2.22) 0.117 0.97 (0.36 to 2.61) 0.949
Marital status
  Living alone 1 – – –
  Living with a partner 0.68 (0.61 to 1.37) 0.67 – –
Education status
  No formal education 1 – –
  Primary school 1.03 (0.58 to 1.83) 0.09 – –
  Secondary school 1.08 (0.56 to 2.09) 0.22 – –
  College/university 0.89 (0.41 to 1.92) 0.761 – –
WHR 1.29 (0.14 to 12.00) 0.821 – –
  Low WHR 1
  High WHR 1.18 (0.65 to 2.12) 0.589 –
eGFR (mL/min/1.73 m²) 1.00 (1.00 to 1.01) 0.139 1.00 (0.99 to 1.02) 0.412
Total serum cholesterol 0.964 (0.80 to 1.16) 0.693 – –
Proteinuria
  No 1 – – –
  Yes 0.48 (0.26 to 0.92) 0.027 0.36 (0.07 to 1.80) 0.213
Use of CCB
  No 1 – – –
  Yes 0.73 (0.72 to 1.61) 0.729 – –
Use of thiazides
  No 1 – – –
  Yes 1.58 (1.06 to 2.37) 0.026 1.44 (0.62 to 3.39) 0.399
Use of ACE inhibitors
  No 1 – – –
Continued
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Characteristic Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
  Yes 0.64 (0.43 to 0.95) 0.028 0.35 (0.14 to 0.85) 0.020
Use of ARB
  No 1 – – –
  Yes 0.95 (0.57 to 1.58) 0.834 – –
Alpha-blocker
  No 1 – – –
  Yes 0.24 (0.09 to 0.68) 0.007 0.76 (0.14 to 4.20) 0.749
Beta-blocker
  No 1 – – –
  Yes 0.70 (0.43 to 1.14) 0.149 0.51 (0.19 to 1.37) 0.184
Optimal glycaemic control
  No 1 – – –
  Yes 2.53 (1.63 to 3.93) <0.001 1.92 (0.71 to 5.23) 0.201
Optimal LDL-C control
  No 1 – – –
  Yes 0.55 (0.23 to 1.36) 0.199 0.75 (0.25 to 2.32) 0.623
*Omitted because of collinearity.
ARB, angiotensin II receptor blocker; BMI, body mass index; CCB, calcium channel blocker; LDL-C, low-density lipoprotein-cholesterol; OHA, 
oral hypoglycaemic agent; WHR, waist:hip ratio; eGFR, estimated glomerular filtration rate.
Table 3 Continued
(56.7% vs 37.1%, p<0.001), have higher WHR (95.2% 
vs 55.9%), be hypertensive (86.1% vs 70.6%, p<0.001), 
and have a higher mean total cholesterol (4.5 mmol/L 
vs 4.3 mmol/L, p=0.030) and LDL-C (2.9 mmol/L vs 2.6 
mmol/L, p=0.006) than male patients. Urine dipstick 
was positive for protein in 10.2% of patients, mostly men 
(15.9% vs 7.3%, p=0.003).
Optimal glycaemic control
The mean (SD) HbA1c was 8.4% (2.4) overall, 8.6% (2.7) 
for female and 8.0% (1.6) for male patients (p=0.199) 
(table 1). The proportion of the patients receiving oral 
hypoglycaemic agents alone was 54.2%; 30% were on oral 
hypoglycaemic agents combined with insulin; 13.6% on 
insulin alone and 2.2% were on a diet alone. Of the 218 
patients on insulin, 184 (84.4%) were on premix insulin. 
Of the 421 patients on oral hypoglycaemic agents, 411 
(97.6%) patients were on metformin, and 194 (46.1%) 
patients were on a sulfonylurea. Compared with patients 
on other antidiabetic medications, those on insulin injec-
tions were more likely to be men. We noted optimal 
glycaemic control in 159 (32.3%) patients, whose mean 
HbA1c was 6.1%. Age over 50 years was associated with 
optimal glycaemic control (AOR 5.79; 95% CI 1.08 to 
31.14). On the other hand, an increase in diabetes dura-
tion was inversely associated with optimal glycaemic 
control (AOR 0.91; 95% CI 0.85 to 0.98). There was no 
association between gender, anthropometry, diabetes 
medications or education on the level of glycaemic 
control (table 2).
Optimal hypertension control
There were 404 (80.8%) hypertensive patients (table 1). 
Age ≥50 years (AOR 4.95; 95% CI 2.81 to 8.73), increased 
WHR (AOR 3.87; 95% CI 1.72 to 8.71), eGFR (AOR 0.98; 
95% CI 0.97 to 0.99) and a long diabetes duration (AOR 
1.07; 95% CI 1.02 to 1.12) were associated with hyper-
tension. Seventeen (4.2%) hypertensive patients did 
not receive any antihypertensive medication. Of the 389 
patients who received antihypertensive medications, 219 
(56.3%) received calcium channel blockers, 189 (48.6%) 
were treated with thiazide diuretics, 183 (47.0%) with ACE 
inhibitors and 74 (19.0%) with angiotensin II receptor 
blockers. The proportions of patients receiving β-blockers 
and α-blockers were 22.4% and 5.4%, respectively.
Of the 389 patients who received antihypertensive 
medicines, optimal hypertension control was noted in 
211 (54.2%) patients. Patients on ACE inhibitors were less 
likely to attain optimal hypertension control compared 
with those who were not on ACE inhibitors (AOR 0.24; 
95% CI 0.09 to 0.59). There was no association between 
gender, anthropometry or education on the level of 
hypertension control (table 3).
Optimal lDl-C control
A total of 225 (45%) patients were receiving lipid-low-
ering drugs, mostly (96.4%) atorvastatin. Of these, 147 
(65.3%) patients had LDL-C measurements available. 
Only 30 (20.4%) achieved the optimal LDL-C control 
target. Women were less likely to achieve optimal LDL-C 
control as compared with men (0.24; 95% CI 0.09 to 
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0.59). There was no association of age, anthropometry or 
education on the level of LDL-C control (table 4).
DIsCussIOn
This outpatient cross-sectional study showed a low propor-
tion of patients with optimal control of glycaemic, hyper-
tension and LDL-C among patients with type 2 diabetes 
attending a diabetes clinic in Botswana. In the multi-
variate analysis, duration of diabetes and age above 50 
years were significantly associated with optimal glycaemic 
control. Being on ACE inhibitors was inversely related to 
optimal hypertension control. Women were less likely to 
attain optimal LDL-C levels than men.
Only 32.3% of our participants achieved optimal 
glycaemic control. Similarly, low levels of glycaemic 
control have also been seen among patients with diabetes 
in Africa.11 13 26 27 The proportion of patients with optimal 
glycaemic control (HbA1c<6.5%) in specialised diabetes 
care centres across six sub-Saharan African countries was 
reported to be 29%.13 Similarly, only 7%–31% of patients 
attained optimal glycaemic control (HbA1c level <7%) in 
other settings in Africa.12 14 27 Consequently, suboptimal 
glycaemic levels are an apparent concern in Botswana 
and also in other African countries. In most studies, the 
majority of the patients have HbA1c >8%, well above the 
recommended target (<7%) required to avoid the devel-
opment of microvascular and macrovascular complica-
tions.12 13 This suboptimal glycaemic control could explain 
the fourfold and tenfold prevalence of sight-threat-
ening diabetic retinopathy and proliferative retinop-
athy, respectively, found among African populations 
compared with their European counterparts.28 Despite 
poor glycaemic control level, only a few of our patients 
were on insulin, suggesting clinical inertia of our clini-
cians in response to low glycaemic control.29 We will be 
investigating this further given concerns with the lack of 
glycaemic control in our patients. Similar to other studies 
in sub-Saharan Africa, the likelihood of attaining optimal 
glycaemic control decreased as the duration of diabetes 
increased.30 There is evidence of a progressive loss of beta-
cell function with increasing diabetes duration.7 Insulin 
production progressively declines over time, leading to 
suboptimal glycaemic control unless higher dosages or 
additional agents are initiated.7 Comparable with reports 
from other studies, older patients in our study were more 
likely to achieve optimal glycaemic control than young 
ones.31 32 It is possible that young patients are less likely 
to be compliant with medication and lifestyle modifica-
tion as compared with their older counterparts. However, 
again we need to research this further before making 
any concrete statements and instigating pertinent quality 
improvement programmes.
We also found a high prevalence (80.8%) of hyperten-
sion among patients attending our specialised diabetes 
clinic. A decade ago, the prevalence of hypertension 
among patients with diabetes in this setting was 61.2%.33 
Our findings may suggest an increasing burden of 
hypertension as seen globally, but also a reflection of the 
improvement in the screening and diagnosis of hyperten-
sion over the past few years.34 We are aware of the compa-
rable high frequencies of hypertension in other African 
studies.13 Consistent with previous studies, patients 
with hypertension were older, more obese, and had 
declining GFR and longer diabetes duration.11 35 Thia-
zide diuretics, calcium channel blockers and ACE inhib-
itors were the three most prescribed antihypertensive 
agents. This finding is in line with the available evidence 
recommending thiazide diuretics and calcium channel 
blockers as the most effective antihypertensives in the 
black population.19 20 35 Optimal hypertension control 
was observed in only 54.2% of the patients on antihy-
pertensives, suggesting an urgent need for initiatives to 
improve the identification and control of hypertension. 
This low control level is a concern given the increased 
mortality if hypertension is not controlled.6 Having said 
this, the proportion of patients with optimal hyperten-
sion control in our population was superior to several 
studies in Africa, notwithstanding the variation of the 
definitions of optimal hypertension control across these 
studies.11–14 35–37 The proportion of type 2 diabetes with 
optimal hypertension in Africa is often below 35%.11 12 37
However, there is no room for complacency. In the 
present study, the use of ACE inhibitors was inversely 
associated with optimal hypertension control. Although 
ACE inhibitors are indicated for patients with diabetes 
and proteinuria, they have a clinically significant lesser 
reduction in both systolic and diastolic blood pressure in 
the black population. This could partly explain subop-
timal hypertension control among predominantly black 
patients in our study. There appeared to be no influence of 
gender on hypertension control similar to other studies,38 
which is encouraging as a recent systematic review found 
that men in low-income and middle-income countries are 
more likely to be non-adherent to their medications.39 40
Less than half of the patients (45%) were on lipid-low-
ering drugs, mostly statins. This is not surprising as the 
prescription of lipid-lowering medications in Africa is 
as low as 3%–13% in patients with diabetes due to the 
limited access to these drugs as well as lack of facilities 
for monitoring lipid profiles while patients are on treat-
ment, regular medication stock-outs and insufficient 
health professionals.13 40 41 It is, however, a concern as 
the reduced use of statins will increase mortality rates in 
patients with diabetes.8 In some countries, the issue of 
co-payments limits the prescription of expensive medi-
cations like statins.42 However, this is not an issue in 
Botswana where medications are provided free of charge 
to patients. Although the lack of co-payments might have 
led to a higher prescription of statins in Botswana than in 
other African countries, we would expect the rate of statin 
prescriptions to mirror the high rates seen in Western 
countries.43 Education and adherence to guidelines 
will possibly improve the prescription and use of statins 
among the majority of patients with diabetes according 
to treatment guidelines.19 21 Even when statins were 
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Table 4 Factors associated with optimal LDL-C control among patients with type 2 diabetes at a specialised diabetes clinic in 
Gaborone (N=500)
Characteristic Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Age group
  <50 years 1 – –
  ≥50 years 0.56 (0.21 to 1.50) 0.249 – –
Diabetes duration, years 1.02 (0.97 to 1.06) 0.525 – –
Use of insulin alone
  No 1 – – –
  Yes 1.58 (0.56 to 4.46) 0.389 – –
Use of OHA alone
  No 1 – – –
  Yes 0.95 (0.43 to 2.12) 0.900 – –
Use of insulin plus OHA
  No 1 – – –
  Yes 0.83 (0.35 to 1.97) 0.664 – –
BMI 1.00 (0.93 to 1.07) 0.951 – –
  Normal weight 1 – – –
  Overweight 1.43 (0.34 to 5.94) 0.624 – –
  Obese 1.27 (0.33 to 4.89) 0.730 – –
Gender
  Male 1 – –
  Female 0.2 (0.09 to 0.47) <0.001 0.24 (0.09 to 0.59) 0.002
Education status
  No formal education 1 1 – –
  Primary school 0.79 (0.29 to 2.14) 0.647 – –
  Secondary school 0.28 (0.07 to 1.20) 0.087 – –
  College/university 0.79 (0.20 to 3.11) 0.731 – –
Marital status
  Living alone 1 – – –
  Living with a partner 0.99 (0.44 to 2.20) 0.973 – –
HbA1c 1.00 (0.85 to 0.20) 0.917 –
WHR 7.59 (0.19 to 303.60) 0.281 – –
  Low WHR 1
  High WHR 0.31 (0.11 to 0.89) 0.030 0.64 (0.20 to 2.10) 0.463
Proteinuria
  No – – –
  Yes 0.69 (0.14 to 3.27) 0.64 – –
eGFR (mL/min/1.73 m²) 1.00 (0.99 to 1.01) 0.878 – –
CKD
  No 1 – – –
  Yes 1.88 (0.73 to 4.83) 0.193 1.67 (0.61 to 4.58) 0.321
Hypertension
  No – – –
  Yes 1.13 (0.30 to 4.23) 0.86 – –
BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein-cholesterol; 
OHA, oral hypoglycaemic agent; WHR, waist:hip ratio.
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used, an undesirably small proportion of our patients 
achieved guideline-recommended LDL-C target level. 
Suboptimal LDL-C control rates are also frequent across 
different settings, even in developed countries.9 13 15 44 
This is disappointing as achieving LDL-C reduction is 
associated with the highest cardiovascular risk reduction 
than hypertension and HbA1c reduction.9 Inadequate 
patients’ adherence and possibly clinicians’ under-dosage 
of statin for fear of potential side effects are some of the 
factors that possibly explain suboptimal LDL-C control 
in our patients.9 Besides, clinicians may be unaware of 
the current LDL-C as well as those of HbA1c and hyper-
tension therapeutic goals.19 21 Irrespective of the reason, 
there is an urgent need to instigate measures to meet 
guideline-recommended therapeutic goals, and we have 
started to address this in our clinic. As reported in other 
studies, women were less likely than men to achieve 
optimal LDL-C control.44 Although the reason for this 
gender difference is not apparent, this information is 
significant for clinicians to pay attention to the manage-
ment of women with diabetes in Botswana and other 
African countries.
To the best of our knowledge, this is the first study to 
objectively assess the three critical therapeutic targets in 
patients with diabetes in one of the few specialised diabetes 
clinics in Botswana. However, our findings should be inter-
preted considering several limitations. First, the study 
was limited to one specialised public diabetes clinic, and 
the findings may not be generalised to other public and 
private facilities in the country. Nevertheless, being the 
leading specialised diabetes clinics in the country, our find-
ings likely represent the ‘best’ quality of diabetes care in 
Botswana. Consequently, highlighted concerns are likely 
to be higher in non-specialist healthcare facilities treating 
patients with type 2 diabetes in Botswana. Second, the study 
was cross-sectional in design and therefore unable to estab-
lish a temporal relationship between the factors associated 
with poor control of glycaemia, LDL-C and hypertension. 
Third, the results may be subject to selection bias because 
of incomplete data in some participants. Another potential 
risk of selection bias is the fact that the study enrolled only 
those patients available at the clinic during the study period. 
As such, patients unable to attend the clinic or those whose 
appointments did not coincide with the study period did 
not participate. Despite these limitations, we believe our 
findings are robust to help improve the care of patients with 
type 2 diabetes in Botswana.
In conclusion, there was suboptimal glycaemic, hyperten-
sion and LDL-C control among patients with diabetes in our 
setting. These findings call for urgent individual and health 
systems interventions to address the factors associated with 
suboptimal control of the cardiovascular risk factors among 
patients with type 2 diabetes in Botswana. This will be the 
subject of future initiatives and research in our clinic given 
the growing prevalence of patients with type 2 diabetes in 
Botswana.
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